© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Nicolas Girard, MD, discusses how to maximize the clinical benefit of crizitonib (Xalkori) in non-small cell lung cancer (NSCLC).